Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX)

Rhea-AI Filing Summary

Celldex Therapeutics reports amended Schedule 13G ownership filing by Kynam Capital. The amendment states 5,840,567 shares of Common Stock are beneficially owned, representing 8.77% of the class. The filing lists shared voting and dispositive power of 5,840,567 shares and is signed by Yue Tang.

The filing names Kynam Capital Management, LP; Kynam Capital Management GP, LLC; and Yue Tang and gives principal addresses for the filer and issuer.

Insights

Institutional Ownership Specialist

Amendment records a passive beneficial stake by Kynam Capital of 8.77%.

The filing shows 5,840,567 shares beneficially owned with shared voting and dispositive power across Kynam entities and an individual, Yue Tang. This reflects the ownership snapshot disclosed in the Schedule 13G/A amendment.

Timing and activity details are limited to the amendment; subsequent filings would show any changes in stake or voting arrangements.

Governance Analyst

Shared control suggests ownership held at the fund/GP level rather than sole individual control.

The document lists identical shared voting/dispositive power for the LP, GP and Yue Tang, indicating the position is reported across related entities. The CUSIP and issuer address are provided for verification.

Review future amendments for changes in percent ownership or shifts from shared to sole power; this filing does not state trading intent.

Key Figures

Beneficially owned shares: 5,840,567 shares Percent of class: 8.77% CUSIP: 15117B202 +2 more

5 metrics

Beneficially owned shares 5,840,567 shares reported in Item 4 of Schedule 13G/A

Percent of class 8.77% Percent of class as stated in the filing

CUSIP 15117B202 Common Stock CUSIP listed on the form

Signature date 05/15/2026 Dates on filing signatures

Header date 03/31/2026 Date appearing in the header of the excerpt

Key Terms

Schedule 13G/A, Beneficially owned, Shared dispositive power, CUSIP

4 terms

Schedule 13G/A regulatory

"Amendment No. 3 Celldex Therapeutics, Inc. Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. Ownership (a) Amount beneficially owned: 5,840,567"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Shared Dispositive Power 5,840,567.00"

CUSIP technical

"CUSIP No.: 15117B202"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

What stake does Kynam Capital report in Celldex Therapeutics (CLDX)?

Kynam Capital reports 5,840,567 shares beneficially owned, equal to 8.77% of the class. The ownership is reported across Kynam Capital Management, GP and the individual filer Yue Tang.

Who is listed as having voting and dispositive power over the reported shares?

The filing lists shared voting and shared dispositive power of 5,840,567 shares for Kynam Capital Management, LP; Kynam Capital Management GP, LLC; and Yue Tang.

When was the Schedule 13G/A signed for this amendment?

The signatures are dated 05/15/2026. The cover line also references 03/31/2026 in the header area of the filing excerpt.

What class of Celldex securities is reported in the filing?

The filing reports ownership of Common Stock, par value $0.001 for Celldex Therapeutics, with CUSIP 15117B202 stated on the form.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Celldex Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

15117B202

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

Kynam Capital Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,840,567.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,840,567.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.77 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

Kynam Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,840,567.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,840,567.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.77 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

Yue Tang

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,840,567.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,840,567.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.77 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Celldex Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NEW JERSEY 08827
Item 2.
(a)	Name of person filing: Kynam Capital Management, LP Kynam Capital Management GP, LLC Yue Tang
(b)	Address or principal business office or, if none, residence: 221 ELM ROAD PRINCETON, New Jersey 08540
(c)	Citizenship: Kynam Capital Management, LP - DELAWARE Kynam Capital Management GP, LLC - DELAWARE Yue Tang - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.001
(e)	CUSIP No.: 15117B202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,840,567
(b)	Percent of class: 8.77 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(ii) Shared power to vote or to direct the vote: Kynam Capital Management, LP - 5,840,567 Kynam Capital Management GP, LLC - 5,840,567 Yue Tang - 5,840,567
	(iii) Sole power to dispose or to direct the disposition of: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(iv) Shared power to dispose or to direct the disposition of: Kynam Capital Management, LP - 5,840,567 Kynam Capital Management GP, LLC - 5,840,567 Yue Tang - 5,840,567
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kynam Capital Management, LP

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	05/15/2026

Kynam Capital Management GP, LLC

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	05/15/2026

Yue Tang

Signature:	Yue Tang
Name/Title:	Self
Date:	05/15/2026